KRAS and cancer: Preclinical data suggest that PDA harboring KRAS G12R or PI3K mutations may be more susceptible to PI3K inhibitors.16,43 Whether patients with KRAS G12R mutated cancers benefit from PI3K pathway inhibitors is yet unknown.